Tuberculosis News

Comment about "Global Fund to Fight AIDS faces $3 billion aid shortfall" Phone Name Comment 0 Monday, 6th July 2009 Global Fund to Fight AIDS faces $3 billion aid shortfall Laura MacInnis, Reuters The Global Fund to Fight AIDS, Tuberculosis and Malaria is facing a budget hole of about $3 billion as the recession dries up foreign aid, according to ...

MDR-TB is particularly dangerous because it can give rise to extensively drug-resistant M. tuberculosis , which requires aggressive treatment using a combination of five different drugs.

Kristin Kremer, Herre Heersma, and Dick Van Soolingen Author affiliations: European Centre for Disease Prevention and Control, Stockholm, Sweden ; and National Institute for Public Health and the Environment, Bilthoven, the Netherlands Abstract Molecular surveillance of multidrug-resistant tuberculosis was implemented in Europe as case reporting in ...

Frank Fahun, N'Dira Sanoussi, Gladys Anyo, Isdore Chola Shamputa, 1 Leen Rigouts, Luc Kestens, Sverin Anagonou, and Franoise Portaels Author affiliations: Laboratoire de Rfrence des Mycobactries, Cotonou, Benin ; and Institute of Tropical Medicine, Antwerp, Belgium Abstract Using geographic information system and molecular tools, we characterized a ...

A Memorandum of Understanding has been signed between Pakistan's National Tuberculosis Control Program and the Karachi-based Ojha Institute of Chest Diseases to provide better services to multidrug-resistant tuberculosis patients.

Manipulating the "switching time" when the immune system activates its most powerful cells against airborne pathogens may lead to more effective treatments for tuberculosis, according to a study published online June 22 in the Proceedings of the National Academy of Sciences .

It is still a matter of debate whether there is an association between infection with Mycobacterium tuberculosis and allergy.

Relapse Associated with Active Disease Caused by Beijing Strain of Mycobacterium tuberculosis 1 William J. Burman, Erin E. Bliven, Lauren Cowan, Lorna Bozeman, Payam Nahid, Lois Diem, and Andrew Vernon, for the Tuberculosis Trials Consortium Author affiliations: Denver Public Health, Denver Colorado, USA ; University of Colorado at Denver Health ...

The journal Lancet Infectious Diseases examines the worldwide spread of extensively drug-resistant tuberculosis .

A fundamental question about how sugar units are strung together into long carbohydrate chains has also pinpointed a promising way to target new medicines against tuberculosis.

INDIANAPOLIS Eli Lilly and Co. will sell its U.S. and Canadian rights to the antibiotic Capastat Sulfate to Akorn, a Lake Forest, Ill., drug company.

The first new tuberculosis drug in 40 years has successfully treated multidrug-resistant tuberculosis patients in a clinical trial in South Africa.

NEW YORK Drug developer Johnson & Johnson announced plans to team up with the Global Alliance for Tuberculosis Drug Development as it continues developing the TB treatment TMC207.

Johnson & Johnson said yesterday it will accelerate the development of its experimental tuberculosis medicine through a partnership with a nonprofit global alliance dedicated to fighting the illness.

This "revolutionary" test will shorten the 2 to 4 months it now takes to detect multidrug-resistant TB down to mere hours, according to Mario Raviglione, MD, director, WHO tuberculosis program.

Queensland Health is investigating how a patient with tuberculosis was mistakenly put on a Qantaslink passenger service from Cairns to the Torres Strait.

Main Category: Tuberculosis Also Included In: Public Health ; MRSA / Drug Resistance Article Date: 08 Jun 2009 - 4:00 PDT The ratification of primary human-rights treaties is not associated with health status changes, according to a team of Canadian researchers, who add the findings "should not be interpreted to mean that human-rights treaties have ...

A mathematical model was designed to explore the impact of three strategies for better tuberculosis case finding.

Promising Interim Results of a Study of TMC207, a New Experimental Drug for Treatment of Multidrug-resistant Tuberculosis By Ronald Baker, PhD Tuberculosis bacillus The June 4, 2009 issue of the New England Journal of Medicine features an article on the new experimental drug TMC207 for the treatment of multi-drug resistant tuberculosis .

Case 18-2009 - A 24-Year-Old Woman with AIDS and Tuberculosis with Progressive Cough, Dyspnea, and Wasting Douglas Wilson, M.B., Ch.B., Roco M. Hurtado, M.D., and Subba Digumarthy, M.D. Presentation of Case Dr.